Komodo Health, the leader in AI-powered healthcare intelligence, today announced a strategic partnership with ZERO Prostate Cancer (ZERO), the nation’s leading prostate cancer advocacy and support ...

More than 17,000 individuals with cancer died from their malignancy within a year of their diagnosis during the COVID-19 pandemic than expected based on previous trends.An evaluation of 1-year ...

Incidental detection has increased with ubiquitous CT/MRI, inflating early-stage ‘small renal mass’ diagnoses and complicating interpretation of a ~5% rise in <50-year incidence. Obesity, hypertension ...

The Inflation Reduction Act (IRA) represents a transformative shift in US health care policy by enabling Medicare to negotiate drug prices for high-expenditure medicatio ...

Hawaii has the longest life expectancy in the United States — a point of pride that physicians say is also creating an urgent ...

February 2026 saw a major biopharma acquisition, four key buyouts, and licensing deals in antibodies, small molecules, and ...

DeepHealth, a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (NASDAQ: RDNT), today unveils at ECR 2026 the industry's most comprehensive portfolio of ...

Namodenoson is a highly selective A3 adenosine receptor (A3AR) agonist, which has shown a compelling safety profile and demonstrated anti-tumor activity in preclinical pancreatic cancer models. The ...

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...

The Prostate Cancer Foundation (PCF) today announced the recipients of its 2025 Challenge Awards, providing over $12 million in funding for 12 multi-institutional, cross-disciplinary research teams ...

Docetaxel added to androgen deprivation therapy (ADT) was the most cost-effective first-line regimen for patients with ...

Researchers found men who ejaculated more often had fewer prostate cancer diagnoses, pointing to a possible biological ...